Productivity improvements in hepatitis C treatment: Impact on efficacy, cost, cost-effectiveness and quality of life

References

• WHO Fact sheet No. 164. Revised October 2000; 2000.
   Google Scholar
• National Institute of Health Consensus Statement. Management of Hepatitis C 1997;15:1–41.
   Google Scholar
• Socialstyrelsen. Yearbook of health and medical care 2002. Stockholm: Socialstyrelsen; 2003.
   Google Scholar
• Kobelt G. Health economics: an introduction to economic evaluations2nd ed. Office of Health Economics, London 2002
   Google Scholar
• Hollander A, Foster G, Weiland O. Health related quality of life prior to, during and after combination therapy with interferon and ribavirin in unselected Swedish patients with chronic hepatitis C. Scand J Gastroenterol 2006; 41: 577–85
   PubMed Web of Science ®Google Scholar
• Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K, Inoue O, et al. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996; 23: 1334–40
   PubMed Web of Science ®Google Scholar
• Yano M, Yatsuhashi H, Inoue O, Inokuchi K, Koga M. Epidemiology and long term prognosis of hepatitis C virus infection in Japan. Gut 1993; 34(Suppl 2)S13–6
   PubMed Web of Science ®Google Scholar
• Yatsuhashi H, Yano M. Natural history of chronic hepatitis C. J Gastroenterol Hepatol 2000; 15 Suppl: E111–6
   PubMed Web of Science ®Google Scholar
• Statistics Sweden. Statistical yearbook of Sweden 2004. Vol 90. Statistics Sweden; 2003.
   Google Scholar
• Lundberg L, Johannesson M, Isacson D, Borgquist L. Health-state utilities in a general population in relation to age, gender and socioeconomic factors. Eur J Public Health 1999; 9: 211–7
   Web of Science ®Google Scholar
• Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825–32
   PubMed Web of Science ®Google Scholar
• Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 463–72
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485–92
   PubMed Web of Science ®Google Scholar
• Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975–82
   PubMed Web of Science ®Google Scholar
• Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958–65
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, Sanchez-Tapias J, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004; 40: 993–9
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Sette H, Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346–55
   PubMed Web of Science ®Google Scholar
• Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34: 395–403
   PubMed Web of Science ®Google Scholar
• Weiland O, Hollander A, Frisell K, Sandell S. Cost-effective therapy for genotype 2 and 3 chronic hepatitis C. Hepatology 2003; 38(Suppl 1)739A
   Google Scholar
• Dalgard O, Bjoro K, Hellum KB, Myrvang B, Ritland S, Skaug K, et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 2004; 40: 1260–5
   PubMed Web of Science ®Google Scholar
• Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005; 352: 2609–17
   PubMed Web of Science ®Google Scholar
• von Wagner M, Huber M, Berg T, Hinrichsen H, Rasenack J, Heintges T, et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005; 129: 522–7
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Buti-ferrer M, Ferenci P, Sperl P, Horsmans Y, Ibranyi E, , et al. Efficacy of 24 weeks treatment with peg_IFN alfa-2b plus ribavirin in patients with chronic hepatitis C infection with genotype 1 and low pre-treatment viremia. J Hepatol 2006;44:97–103.
   PubMed Web of Science ®Google Scholar
• Berg T, Wagner M, Hinrichsen H, Heintges T, Buggisch P, Goeser T, , et al. Reduction of relative relapse rates by prolongation of the duration of therapy with peginterferon-alfa-2a plus ribavirin up to 72 weeks in patients with HCV type 1 infection. Gastroenterology 2006;130:1086–97.
   PubMed Web of Science ®Google Scholar
• National Medicine Information System. http://www.fass.se.
   Google Scholar
• Sennfalt K, Reichard O, Hultkrantz R, Wong JB, Jonsson D. Cost-effectiveness of interferon alfa-2b with and without ribavirin as therapy for chronic hepatitis C in Sweden. Scand J Gastroenterol 2001; 36: 870–6
   PubMed Web of Science ®Google Scholar
• McHorney CA, Ware JE, Jr, Lu JF, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 1994; 32: 40–66
   PubMed Web of Science ®Google Scholar
• McHorney CA, Ware JE, Jr, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993; 31: 247–63
   PubMed Web of Science ®Google Scholar
• Bonkovsky HL, Woolley JM. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group. Hepatology 1999; 29: 264–70
   PubMed Web of Science ®Google Scholar
• Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998; 27: 209–12
   PubMed Web of Science ®Google Scholar
• Ware JE, Jr, Bayliss MS, Mannocchia M, Davis GL. Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. The Interventional Therapy Group. Hepatology 1999; 30: 550–5
   PubMed Web of Science ®Google Scholar
• Lundberg L, Johannesson M, Isacson DG, Borgquist L. The relationship between health-state utilities and the SF-12 in a general population. Med Decision-Making 1999; 19: 128–40
   PubMed Web of Science ®Google Scholar
• Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997; 127: 855–65
   PubMed Web of Science ®Google Scholar
• Kim WR, Poterucha JJ, Hermans JE, Therneau TM, Dickson ER, Evans RW, et al. Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C. Ann Intern Med 1997; 127: 866–74
   PubMed Web of Science ®Google Scholar
• Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 2003; 290: 228–37
   PubMed Web of Science ®Google Scholar
• Siebert U, Sroczynski G, Rossol S, Wasem J, Ravens-Sieberer U, Kurth BM, et al. Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 2003; 52: 425–32
   PubMed Web of Science ®Google Scholar
• Sullivan SD, Craxi A, Alberti A, Giuliani G, De Carli C, Wintfeld N, et al. Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C. Pharmacoeconomics 2004; 22: 257–65
   PubMed Web of Science ®Google Scholar
• Wong JB, Bennett WG, Koff RS, Pauker SG. Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs. JAMA 1998; 280: 2088–93
   PubMed Web of Science ®Google Scholar
• Wong JB, Davis GL, McHutchison JG, Manns MP, Albrecht JK. Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C. Am J Gastroenterol 2003; 98: 2354–62
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Singer ME, McHutchison JG, Shermock KM. Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology 1999; 30: 1318–24
   PubMed Web of Science ®Google Scholar
• Gines P, Quintero E, Arroyo V, Teres J, Bruguera M, Rimola A, et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology 1987; 7: 122–8
   PubMed Web of Science ®Google Scholar
• Colombo M, de Franchis R, Del Ninno E, Sangiovanni A, De Fazio C, Tommasini M, et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991; 325: 675–80
   PubMed Web of Science ®Google Scholar
• Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993; 328: 1797–801
   PubMed Web of Science ®Google Scholar
• Ascher NL, Lake JR, Emond J, Roberts J. Liver transplantation for hepatitis C virus-related cirrhosis. Hepatology 1994; 20: 24S–7S
   PubMed Web of Science ®Google Scholar
• Detre K, Belle S, Lombardero M. Liver transplantation for chronic viral hepatitis. Viral Hepatitis Rev 1996; 2: 219–28
   Web of Science ®Google Scholar
• Kilpe VE, Krakauer H, Wren RE. An analysis of liver transplant experience from 37 transplant centers as reported to Medicare. Transplantation 1993; 56: 554–61
   PubMed Web of Science ®Google Scholar